POLXF — Polydex Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro Cap

Annual income statement for Polydex Pharmaceuticals, fiscal year end - January 31st, USD millions except per share, conversion factor applied.

	2017 January 31st	2018 January 31st	2019 January 31st	2020 January 31st	2021 January 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	6.62	5.28	4.94	5.14	4.86
Cost of Revenue
Gross Profit	1.82	1.3	0.928	1.04	0.97
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Operating Interest Expense / Income
Unusual Expense / Income
Total Operating Expenses	5.77	4.8	4.77	4.89	4.65
Operating Profit	0.856	0.482	0.17	0.252	0.21
Net Income Before Taxes	0.856	0.482	0.17	0.252	0.21
Provision for Income Taxes
Net Income After Taxes	0.669	0.448	0.231	0.251	0.212
Net Income Before Extraordinary Items
Net Income	0.669	0.448	0.231	0.251	0.212
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	0.669	0.448	0.231	0.251	0.212
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.191	0.129	0.067	0.088	0.062